Diabetology Ltd
From Wikipedia, the free encyclopedia
| Type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | Jersey (November 13, 2002) |
| Headquarters | Saint Helier, Jersey (registered office) |
| Key people |
Roger New (CSO) Glen Travers |
| Products | 2 in clinical development and 3 in pre-clinical development |
| Website | www.diabetology.co.uk |
Diabetology Ltd is a biopharmaceutical company registered in Saint Helier, Jersey.[1]
It was founded in November 2002 and is developing oral drugs for the treatment of diabetes mellitus.[2]
Products
Currently, the company doesn't have a marketed product, though its pipeline includes one drug that has recently completed phase II clinical development, one in phase II clinical development, and three in pre-clinical development.[3]
| Drug | Phase | Action |
|---|---|---|
| Capsulin OAD | Phase II clinical trial completed | Oral insulin for diabetes mellitus type 2 |
| Capsulin IR | Phase II clinical trial | Oral insulin for diabetes mellitus type 1 |
| Combulin | Pre-clinical development | Oral combination of insulin and insulin sensitizing agents for diabetes mellitus type 2 |
| Oral GLP-1 | Pre-clinical development | Improves glycaemic and diet control in diabetes mellitus type 2 |
| Oral C-Petdide | Pre-clinical development | Reduces diabetic complications |
References
External links
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.